Back to Search
Start Over
Telmisartan: just an antihypertensive agent? A literature review.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2011 Dec; Vol. 12 (17), pp. 2719-35. - Publication Year :
- 2011
-
Abstract
- Introduction: The modulation of the renin angiotensin aldosterone system (RAAS) is an important pathway in managing high blood pressure, and its overexpression plays a key role in target end-organ damage. Telmisartan is an angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including the longest half-life among all ARBs; this leads to a significant and 24-h sustained reduction of blood pressure. Telmisartan has well-known antihypertensive properties, but there is also strong clinical evidence that it reduces left ventricular hypertrophy, arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection.<br />Areas Covered: This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications.<br />Expert Opinion: ONTARGET (ongoing telmisartan alone and in combination with ramipril global endpoint trial) demonstrated, that telmisartan confers cardiovascular protective effects similar to those of ramipril, but with a better tolerability. Moreover, recent investigations focused on the capability of telmisartan to modulate the peroxisome proliferator-activated receptor-gamma (PPAR-γ), an established target in the treatment of insulin resistance, diabetes and metabolic syndrome, whose activation is also correlated to anti-inflammatory and, finally, anti-atherosclerotic properties. Telmisartan shows peculiar features that go beyond blood pressure control. It presents promising and unique protective properties against target end-organ damage, potentially able to open a scenario of new therapeutic approaches to cardiovascular disease.
- Subjects :
- Angiotensin II Type 1 Receptor Blockers economics
Angiotensin II Type 1 Receptor Blockers pharmacology
Animals
Antihypertensive Agents economics
Antihypertensive Agents pharmacology
Atrial Fibrillation prevention & control
Benzimidazoles economics
Benzimidazoles pharmacology
Benzoates economics
Benzoates pharmacology
Costs and Cost Analysis
Humans
Hypertension economics
Hypertension metabolism
Hypertrophy, Left Ventricular prevention & control
Kidney Diseases prevention & control
Renin-Angiotensin System
Telmisartan
Angiotensin II Type 1 Receptor Blockers therapeutic use
Antihypertensive Agents therapeutic use
Benzimidazoles therapeutic use
Benzoates therapeutic use
Hypertension drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 12
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 22077832
- Full Text :
- https://doi.org/10.1517/14656566.2011.632367